SUDEEPPHRM

What Sudeep Pharma promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 21 tracked 1 delivered 1 missed 19 open
  • Revenue Growth delivered, diluted said Q2 FY26 Promised: Sustain 26% growth for the remainder of the year. Q1 FY27: Promise concluded in the previous fiscal year (FY26).
  • EBITDA Margin missed said Q2 FY26 Promised: Maintain above 35% going forward. Q1 FY27: Q1 FY27 EBITDA margin was 34.7%, remaining below the original >35% target.
  • Working Capital Days revised down said Q2 FY26 Promised: Moderate and sustain approximately around 140 to 150 days over the medium term. Q1 FY27: Management revised near-term working capital target to 170 days (ex-battery), a dilution from the original 140-150 day medium-term goal.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 21 tracked commitments for Sudeep Pharma — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens